Related Experiment Videos
Invasive Strategies to Achieve Infarct-Related Artery Patency
1Tufts University School of Medicine; Adult Cardiac Catheterization Laboratory and Experimental Cardiovascular Imaging and Interventions Laboratory, New England Medical Center, Boston, Massachusetts, USA.
Insights
Maintaining an open artery after myocardial infarction improves patient outcomes. While thrombolytic therapy is common, primary angioplasty is preferred for select acute myocardial infarction patients, especially those with contraindications to thrombolysis.
Area of Science:
- Cardiology
- Interventional Cardiology
- Acute Myocardial Infarction Management
Background:
- The open-artery hypothesis suggests that patent infarct-related arteries improve outcomes after myocardial infarction.
- Patients with open arteries experience fewer complications, better ventricular remodeling, and improved survival.
- Thrombolytic therapy has been the standard for acute myocardial infarction (AMI), particularly in community settings.
Purpose of the Study:
- To review the role of reperfusion strategies in acute myocardial infarction (AMI).
- To evaluate the efficacy and appropriate use of mechanical reperfusion therapies like angioplasty.
- To discuss the cost-effectiveness and value-based considerations in reperfusion therapy.
Main Methods:
- Review of randomized trials and clinical data on reperfusion therapies over the past decade.
- Comparison of thrombolytic therapy versus mechanical reperfusion (angioplasty) for AMI.
- Analysis of outcomes in patients undergoing different reperfusion strategies, including those with failed thrombolysis or recurrent ischemia.
Main Results:
- Open infarct-related arteries are associated with improved myocardial infarction outcomes.
- Primary angioplasty is a preferred reperfusion strategy for selected AMI patients, including those in cardiogenic shock or with thrombolytic contraindications.
- Mechanical reperfusion is effective for failed thrombolysis or recurrent ischemia, but routine angioplasty for all reperfused arteries lacks strong supporting data.
Conclusions:
- Mechanical reperfusion, particularly primary angioplasty, offers significant benefits for specific acute myocardial infarction patient groups.
- The decision for reperfusion therapy should consider clinical effectiveness, patient selection, and cost-effectiveness.
- Value and clinical efficacy will increasingly drive treatment choices in managed care environments.
Abstract:
Randomized trials of reperfusion therapy completed over the past decade have engendered the open-artery hypothesis. Collectively, patients with patent infarct-related arteries have fewer complications of their myocardial infarction, salutary effects on ventricular remodeling, and better survival. Thrombolytic therapy has been widely regarded as the most appropriate initial therapy for acute myocardial infarction (AMI), particularly in the community setting. At institutions with the appropriate resources and expertise, primary angioplasty may be the treatment of choice for patients with AMI presenting within 6 hours. Mechanical reperfusion strategies such as angioplasty are quite effective and may be more appropriate for selected patient populations, such as those in cardiogenic shock or who have compelling contraindications to thrombolytic therapy. For these patients, timely mechanical reperfusion can lead to prompt hemodynamic stability and significant improvement in prognosis. Balloon angioplasty, and to a lesser extent other mechanical interventions, are effective therapy for patients with failed thrombolysis or recurrent spontaneous ischemia after initial reperfusion therapy. Elective mechanical revascularization after AMI can be performed with a high degree of success, a low rate of complication, and a good long-term outcome, but there are no compelling data to support routine angioplasty, ostensibly to create an "open artery", for patients with clinical reperfusion and no spontaneous or inducible ischemia. Finally, all interventions, whether chemical or mechanical, will be required to be cost effective as well as clinically effective. As we move to a managed care environment in the latter half of this decade, value will replace technology as the prominent influence in American medicine.